EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Directorate B - Health systems, medical products and innovation
B5 – Medicines – policy, authorisation and monitoring
Head of unit

Brussels, 22 May 2018

NOTE TO THE MEMBERS OF THE STANDING COMMITTEE ON MEDICINAL PRODUCTS FOR HUMAN USE/STANDING COMMITTEE ON VETERINARY MEDICINAL PRODUCTS

Subject: **Adoption of COMMISSION IMPLEMENTING DECISION granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Zessly - infliximab", a medicinal product for human use**

EU/1/18/1280 - EMEA/H/C/4647

The Commission has adopted the abovementioned Decision on 18 May 2018.

The Decision will be notified forthwith to the addressee(s) of the Decision.[1]

The Decision is going to be published for information in all official languages of the EU in the Community Register of Medicinal Products (http://ec.europa.eu/health/documents/community-register/index_en.htm) after the Decision has been notified. The attention has to be drawn to the fact that, under the general rules of the EC Treaty, a Decision is a legal act whose publication is not obligatory in order to be binding.

Olga Solomon
pp. Mihail Patrascu

Cc: Marketing authorisation holder (Contact person, only in centralised procedure);

EMA (Product team leader, secretary)

[1] In case of centralised procedure: Marketing Authorization Holder; In case of referral procedure: Member States (via the Permanent Representations to the European Union)

Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11.
Office: B232 06/094. Telephone: direct line (32-2) 2955959. Fax: (32-2) 2998046.
E-mail: Olga.Solomon@ec.europa.eu